Abstract:Background and PurposeTransient receptor potential canonical (TRPC) channels play important roles in a broad array of physiological functions and are involved in various diseases. However, due to a lack of potent subtype-specific inhibitors the exact roles of TRPC channels in physiological and pathophysiological conditions have not been elucidated.Experimental ApproachUsing fluorescence membrane potential and Ca2+ assays and electrophysiological recordings, we characterized new 2-aminobenzimidazole-based small molecule inhibitors of TRPC4 and TRPC5 channels identified from cell-based fluorescence high-throughput screening.Key ResultsThe original compound, M084, was a potent inhibitor of both TRPC4 and TRPC5, but was also a weak inhibitor of TRPC3. Structural modifications of the lead compound resulted in the identification of analogues with improved potency and selectivity for TRPC4 and TRPC5 channels. The aminobenzimidazole derivatives rapidly inhibited the TRPC4- and TRPC5-mediated currents when applied from the extracellular side and this inhibition was independent of the mode of activation of these channels. The compounds effectively blocked the plateau potential mediated by TRPC4-containing channels in mouse lateral septal neurons, but did not affect the activity of heterologously expressed TRPA1, TRPM8, TRPV1 or TRPV3 channels or that of the native voltage-gated Na+, K+ and Ca2+ channels in dissociated neurons.Conclusions and ImplicationsThe TRPC4/C5-selective inhibitors developed here represent novel and useful pharmaceutical tools for investigation of physiological and pathophysiological functions of TRPC4/C5 channels.

Natural product inspired optimization of a selective TRPV6 calcium channel inhibitor

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Rational Design and Validation of a Vanilloid-Sensitive TRPV2 Ion Channel.

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Identification of Two Natural Coumarin Enantiomers for Selective Inhibition of TRPV2 Channels

Identification and Optimization of 2‐aminobenzimidazole Derivatives As Novel Inhibitors of TRPC4 and TRPC5 Channels

The Discovery of Novel ACA Derivatives As Specific TRPM2 Inhibitors That Reduce Ischemic Injury Both in Vitro and in Vivo.

Experimental and computational biophysics to identify vasodilator drugs targeted at TRPV2 using agonists based on the probenecid scaffold

Inactivation-mimicking block of the epithelial calcium channel TRPV6

Discovery of α‐Obscurine Derivatives as Novel Cav3.1 Calcium Channel Blockers

Novel marine natural products as effective TRPV1 channel blockers

Discovery of N -(1,4-Benzoxazin-3-one) urea analogs as Mode-Selective TRPV1 antagonists

Design, Synthesis and Biological Evaluation of Novel 2,3,4,9-Tetrahydro-1h-pyrido[3,4-b]indole Triazole Derivatives As Potent TRPV1 Antagonists.

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Α-Aryl Pyrrolidine Sulfonamides As TRPA1 Antagonists

Synthesis, high-throughput screening and pharmacological characterization of β–lactam derivatives as TRPM8 antagonists

Discovery of N -(1-(2-hydroxyethyl)quinolin-2-one)- N '-(1-phenyl-1H-pyrazol-5-yl)methyl) urea as Mode-Selective TRPV1 antagonist

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist